DrugPatentWatch Database Preview
Immune globulin intravenous (human) - Biologic Drug Details
Email this page to a colleague
Summary for immune globulin intravenous (human)
| Tradenames: | 6 |
| Patents: | 167 |
| Applicants: | 6 |
| BLAs: | 8 |
| Suppliers: see list | 7 |
| Recent Clinical Trials: | See clinical trials for immune globulin intravenous (human) |
Recent Clinical Trials for immune globulin intravenous (human)
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Grifols Therapeutics LLC | Phase 2 |
| Instituto Grifols, S.A. | Phase 2 |
| Chang Gung Memorial Hospital | Phase 1 |
Pharmacology for immune globulin intravenous (human)
| Mechanism of Action | Antigen Neutralization |
| Physiological Effect | Passively Acquired Immunity |
| Established Pharmacologic Class | Human Immunoglobulin G |
| Chemical Structure | Immunoglobulins |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for immune globulin intravenous (human) Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for immune globulin intravenous (human) Derived from Company Disclosures
No patents found based on company disclosures
3) Low Certainty: US Patents for immune globulin intravenous (human) Derived from Patent Text Search
No patents found based on company disclosures
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2021 - 2022
NCE-1 Patent Challenge Dates 2021 - 2022
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2021, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
